A phase II study of everolimus (RAD001), an mTOR inhibitor plus CHOP for newly diagnosed peripheral T-cell lymphomas
Seung Ju Kim(University of Nebraska–Lincoln), Woo Seob Kim(Samsung Medical Center), Dok Hyun Yoon(Ulsan College), Dong-Yeop Shin(Kongju National University), Hae Young Yoo(Samsung (South Korea)), Young Hyeh Ko(Cheju Halla General Hospital), Cheolwon Suh(Ulsan College), Min Eui Hong(Jiangsu T-mab BioPharma (China)), H. Lee(Hematology\Oncology Clinic), S.H. Lee(Sungkyunkwan University), Hyeon‐Seok Eom(National Cancer Center), Jin Sung Kim(Yonsei University), Young-Rok Do(Keimyung University Dongsan Medical Center), Hye Jin Kang(Korea Institute of Radiological and Medical Sciences), W.S. Lee(Inje University Busan Paik Hospital)
Cited by 54
Related Papers
Matrix elasticity of void-forming hydrogels controls transplanted-stem-cell-mediated bone formation
|Nature Materials|2015|513
Natural history of relapsed myeloma, refractory to immunomodulatory drugs and proteasome inhibitors: a multicenter IMWG study
|Leukemia|2017|356
Overall Survival with Brentuximab Vedotin in Stage III or IV Hodgkin’s Lymphoma
|New England Journal of Medicine|2022|342
Emission color variation of M2SiO4:Eu2+ (M=Ba, Sr, Ca) phosphors for light-emitting diode
|Solid State Communications|2004|224